Early triple antiviral therapy for COVID-19

Early triple antiviral therapy for COVID-19

Bibliographic Details
Main Authors:	Lee, N, Ison, M, Dunning, WJ
Format:	Journal article
Language:	English
Published:	Elsevier 2020

Similar Items

Accelerating antiviral drug discovery: lessons from COVID-19
by: von Delft, A, et al.
Published: (2023)

Repurposed antiviral drugs for Covid-19 - Interim WHO Solidarity trial results
by: Pan, H, et al.
Published: (2020)

Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open-label, randomised, controlled, adaptive platform trial
by: Luvira, V, et al.
Published: (2024)

Platform adaptive trial of novel antivirals for early treatment of COVID-19 In the community (PANORAMIC): protocol for a randomised, controlled, open-label, adaptive platform trial of community novel antiviral treatment of COVID-19 in people at increased risk of more severe disease
by: Gbinigie, O, et al.
Published: (2023)

Delayed mucosal antiviral responses despite robust peripheral inflammation in fatal COVID-19
by: Sidhu, JK, et al.
Published: (2023)

COVID-19 can be called a treatable disease only after we have antivirals
by: Zhang, X, et al.
Published: (2022)

COVID-19, seasonal influenza and measles: potential triple burden and the role of flu and MMR vaccines
by: Islam, N, et al.
Published: (2020)

Symptomatic COPD: is it time for triple therapy?
by: Bafadhel, M
Published: (2018)

A review with updated perspectives on the antiviral potentials of traditional medicinal plants and their prospects in antiviral therapy
by: Saifulazmi, Nur Fadlin, et al.
Published: (2022)

A painful lesson from the COVID-19 pandemic: the need for broad-spectrum, host-directed antivirals
by: Chitalia, Vipul C., et al.
Published: (2020)

Antiviral effect of triple helix-forming oligonucleotides on feline infectious peritonitis virus infection in vitro
by: Choong, Oi Kuan
Published: (2012)

Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial
by: Schilling, WHK, et al.
Published: (2023)

Triple therapy immunosuppression in cadaveric renal transplantation.
by: Richardson, A, et al.
Published: (1990)

Antibiotic therapy in the treatment of COVID-19 pneumonia: who and when?
by: Ng, Tat Ming, et al.
Published: (2023)

Targeting the host ER alpha glucosidases I and II as antiviral therapy
by: Branza-Nichita, N, et al.
Published: (2007)

Early-life experience and CEOs’ reactions to COVID-19
by: Ru, Hong, et al.
Published: (2024)

Toward a Practical, Nonenzymatic Process for Investigational COVID-19 Antiviral Molnupiravir from Cytidine: Supply-Centered Synthesis
by: Gopalsamuthiram, Vijayagopal, et al.
Published: (2022)

Targeting the Achilles heel of mosquito-borne viruses for antiviral therapy
by: Jackman, Joshua A., et al.
Published: (2021)

High-dose budesonide for early COVID-19 - Authors' reply
by: Hobbs, FDR, et al.
Published: (2021)

Passive immune therapies: another tool against COVID-19
by: Escourt, L
Published: (2021)

Detection of significant antiviral drug effects on COVID-19 with reasonable sample sizes in randomized controlled trials: a modeling study
by: Iwanami, S, et al.
Published: (2021)

In vitro antiviral activity of circular triple helix forming oligonucleotide RNA towards feline infectious peritonitis virus replication
by: Choong, Oi Kuan, et al.
Published: (2014)

The impact of COVID-19 on care of early inflammatory arthritis in the UK
by: MacPhie, E, et al.
Published: (2022)

The potential for repurposing anti-TNF as a therapy for the treatment of COVID-19
by: Robinson, PC, et al.
Published: (2020)

Is triple artemisinin-based combination therapy necessary for uncomplicated malaria?
by: van der Pluijm, RW, et al.
Published: (2022)

Privacy-aware early detection of COVID-19 through adversarial training
by: Rohanian, M, et al.
Published: (2022)

An antiviral composition.
by: Abu Bakar, Fatimah, et al.
Published: (2011)

Virologist: Covid -19 cases in a single day may exceed 20,000 again, antiviral medication use should be expanded
by: Guang Ming Daily
Published: (2022)

Global sharing of COVID-19 therapies during a "New Normal"
by: Jecker, NS, et al.
Published: (2022)

Polymorphisms in the host CYP2C19 gene and antibiotic-resistance attributes of Helicobacter pylori isolates influence the outcome of triple therapy
by: Ram M., Ravishankar, et al.
Published: (2018)

The association between socioeconomic status and mobility reductions in the early stage of England’s COVID-19 epidemic
by: Lee, WD, et al.
Published: (2021)

Triple therapy combinations for the treatment of type 2 diabetes – a network meta-analysis
by: Woodward, M, et al.
Published: (2016)

COVID-19
by: Ma, Zexin, et al.
Published: (2023)

Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed
by: Feldmann, M, et al.
Published: (2020)

Circular RNA TFO as antiviral therapy against feline infectious peritonitis virus
by: Choong, Oi Kuan, et al.
Published: (2012)

Curcumin encapsulated chitosan nanoparticles as antiviral therapy against feline infectious peritonitis
by: Ng, Shing Wei
Published: (2018)

Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C.
by: Butera, D, et al.
Published: (2005)

Critical care management of patients with COVID-19: early experience in Thailand
by: Ratanarat, R, et al.
Published: (2020)

Transmissibility prediction of coronavirus disease (covid-19) outbreak in early stages
by: Wong, Jordan, et al.
Published: (2021)

Covid -19 pandemic change to endemic, experts too early to say
by: China Press
Published: (2021)